Fernández DN

Language: Spanish
References: 9
Page:
PDF size: 194.65 Kb.

Text Extraction

No abstract.

REFERENCES

1. Turkington RC, Arnold EC, Percy MJ, Rsnsghsn LA, Cuthbrt RJ, McMulling MF. Comparison of diagnostic criteria for polycythaemia vera. Hematology 2007 Apr; 12(2): 123-30.

2. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114:937-51.

3. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Layout C et al. A unique clonal mutation leading to consecutive signaling causes polycythaemia vera. Nature. 2005;434(7037):1144-8

4. Finazzi G, Barbui T. The treatment of polycythemia vera: an update in the JAK2 era. Intern Emerg Med. 2007; 2:13-18.

5. Scott LM. The JAK2 exon 12 mutations. A comprehensive review. Am J Hematol. 2011; 86:668-76

6. Vainchenker W,Delhommeau F, Constantinescu SN and Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118(7):1723-35

7. Guglielmelli P, Barosi G, Pieri L, Antonioli E, Bosi A and Vannucchi AM. JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythaemia vera and postessential thrombocytemia myelofibrosis. Hematologica. 2009;94(1):144-6

8. Passamonti F, Maffioli M, Caramazza D. New generation small-molecule inhibitors in myeloproliferative neoplasms. Curr Opin Hematol. 2012 Mar;19(2):117-23. doi: 10.1097/MOH.0b013e32834ff575.

9. Cervante F, Mesa R, Harrison C. JAK inhibitors:beyond spleen and symptoms?. Haematologica. 2013; 98(2):160-62.